|
1
|
Lu J and Holmgren A: The thioredoxin
antioxidant system. Free Radic Biol Med. 66:75–87. 2014. View Article : Google Scholar
|
|
2
|
Chen B, Nelin VE, Locy ML, Jin Y and
Tipple TE: Thioredoxin-1 mediates hypoxia-induced pulmonary artery
smooth muscle cell proliferation. Am J Physiol Lung Cell Mol
Physiol. 305:L389–L395. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bobba A, Casalino E, Petragallo VA and
Atlante A: Thioredoxin/thioredoxin reductase system involvement in
cerebellar granule cell apoptosis. Apoptosis. 19:1497–1508. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Laborde E: Glutathione transferases as
mediators of signaling pathways involved in cell proliferation and
cell death. Cell Death Differ. 17:1373–1380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cadenas C, Franckenstein D, Schmidt M,
Gehrmann M, Hermes M, Geppert B, Schormann W, Maccoux LJ, Schug M,
Schumann A, et al: Role of thioredoxin reductase 1 and thioredoxin
interacting protein in prognosis of breast cancer. Breast Cancer
Res. 12:R442010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iwasawa S, Yamano Y, Takiguchi Y, Tanzawa
H, Tatsumi K and Uzawa K: Upregulation of thioredoxin reductase 1
in human oral squamous cell carcinoma. Oncol Rep. 25:637–644.
2011.PubMed/NCBI
|
|
7
|
Fu JN, Li J, Tan Q, Yin HW, Xiong K, Wang
TY, Ren XY and Zeng HH: Thioredoxin reductase inhibitor ethaselen
increases the drug sensitivity of the colon cancer cell line LoVo
towards cisplatin via regulation of G1 phase and reversal of G2/M
phase arrest. Invest New Drugs. 29:627–636. 2011. View Article : Google Scholar
|
|
8
|
Lin T, Ding Z, Li N, Xu J, Luo G, Liu J
and Shen J: 2-Tellurium-bridged β-cyclodextrin, a thioredoxin
reductase inhibitor, sensitizes human breast cancer cells to
TRAIL-induced apoptosis through DR5 induction and NF-κB
suppression. Carcinogenesis. 32:154–167. 2011. View Article : Google Scholar
|
|
9
|
Liang YW, Zheng J, Li X, Zheng W and Chen
T: Selenadiazole derivatives as potent thioredoxin reductase
inhibitors that enhance the radiosensitivity of cancer cells. Eur J
Med Chem. 84:335–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kiebala M, Skalska J, Casulo C, Brookes
PS, Peterson DR, Hilchey SP, Dai Y, Grant S, Maggirwar SB and
Bernstein SH: Dual targeting of the thioredoxin and glutathione
antioxidant systems in malignant B cells: A novel synergistic
therapeutic approach. Exp Hematol. 43:89–99. 2015. View Article : Google Scholar
|
|
11
|
Isakov E, Weisman-Shomer P and Benhar M:
Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in
macrophages by the thioredoxin reductase inhibitor auranofin.
Biochim Biophys Acta. 1840:3153–3161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu N, Li X, Huang H, Zhao C, Liao S, Yang
C, Liu S, Song W, Lu X, Lan X, et al: Clinically used antirheumatic
agent auranofin is a proteasomal deubiquitinase inhibitor and
inhibits tumor growth. Oncotarget. 5:5453–5471. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park SH, Lee JH, Berek JS and Hu MC:
Auranofin displays anticancer activity against ovarian cancer cells
through FOXO3 activation independent of p53. Int J Oncol.
45:1691–1698. 2014.PubMed/NCBI
|
|
14
|
Fan C, Zheng W, Fu X, Li X, Wong YS and
Chen T: Enhancement of auranofin-induced lung cancer cell apoptosis
by selenocystine, a natural inhibitor of TrxR1 in vitro and in
vivo. Cell Death Dis. 5:e11912014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mansfield AS, Roden AC, Peikert T, Sheinin
YM, Harrington SM, Krco CJ, Dong H and Kwon ED: B7-H1 expression in
malignant pleural mesothelioma is associated with sarcomatoid
histology and poor prognosis. J Thorac Oncol. 9:1036–1040. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kahlos K, Soini Y, Säily M, Koistinen P,
Kakko S, Pääkkö P, Holmgren A and Kinnula VL: Up-regulation of
thioredoxin and thioredoxin reductase in human malignant pleural
mesothelioma. Int J Cancer. 95:198–204. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han S and Kim K, Kim H, Kwon J, Lee YH,
Lee CK, Song Y, Lee SJ, Ha N and Kim K: Auranofin inhibits
overproduction of pro-inflammatory cytokines, cyclooxygenase
expression and PGE2 production in macrophages. Arch Pharm Res.
31:67–74. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suarez-Almazor ME, Spooner CH, Belseck E
and Shea B: Auranofin versus placebo in rheumatoid arthritis.
Cochrane Database Syst Rev. 2:CD0020482000.PubMed/NCBI
|
|
19
|
Kim NH, Park HJ, Oh MK and Kim IS:
Antiproliferative effect of gold(I) compound auranofin through
inhibition of STAT3 and telomerase activity in MDA-MB 231 human
breast cancer cells. BMB Rep. 46:59–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park N and Chun YJ: Auranofin promotes
mitochondrial apoptosis by inducing annexin A5 expression and
translocation in human prostate cancer cells. J Toxicol Environ
Health A. 77:1467–1476. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Papaioannou M, Mylonas I, Kast RE and
Brüning A: Disulfiram/copper causes redox-related proteotoxicity
and concomitant heat shock response in ovarian cancer cells that is
augmented by auranofin-mediated thioredoxin inhibition.
Oncoscience. 1:21–29. 2014.
|
|
22
|
Lincoln DT, Al-Yatama F, Mohammed FM,
Al-Banaw AG, Al-Bader M, Burge M, Sinowatz F and Singal PK:
Thioredoxin and thioredoxin reductase expression in thyroid cancer
depends on tumour aggressiveness. Anticancer Res. 30:767–775.
2010.PubMed/NCBI
|
|
23
|
Eriksson SE, Prast-Nielsen S, Flaberg E,
Szekely L and Arnér ES: High levels of thioredoxin reductase 1
modulate drug-specific cytotoxic efficacy. Free Radic Biol Med.
47:1661–1671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ferrer MD, Sureda A, Tauler P, Palacín C,
Tur JA and Pons A: Impaired lymphocyte mitochondrial antioxidant
defences in variegate porphyria are accompanied by more inducible
reactive oxygen species production and DNA damage. Br J Haematol.
149:759–767. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Scarbrough PM, Mapuskar KA, Mattson DM,
Gius D, Watson WH and Spitz DR: Simultaneous inhibition of
glutathione- and thioredoxin-dependent metabolism is necessary to
potentiate 17AAG-induced cancer cell killing via oxidative stress.
Free Radic Biol Med. 52:436–443. 2012. View Article : Google Scholar
|
|
26
|
Lopert P, Day BJ and Patel M: Thioredoxin
reductase deficiency potentiates oxidative stress, mitochondrial
dysfunction and cell death in dopaminergic cells. PLoS One.
7:e506832012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dunning S, Ur Rehman A, Tiebosch MH,
Hannivoort RA, Haijer FW, Woudenberg J, van den Heuvel FA,
Buist-Homan M, Faber KN and Moshage H: Glutathione and antioxidant
enzymes serve complementary roles in protecting activated hepatic
stellate cells against hydrogen peroxide-induced cell death.
Biochim Biophys Acta. 1832:2027–2034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iversen R, Andersen PA, Jensen KS, Winther
JR and Sigurskjold BW: Thiol-disulfide exchange between
glutaredoxin and glutathione. Biochemistry. 49:810–820. 2010.
View Article : Google Scholar
|
|
29
|
Kumar C, Igbaria A, D'Autreaux B, Planson
AG, Junot C, Godat E, Bachhawat AK, Delaunay-Moisan A and Toledano
MB: Glutathione revisited: A vital function in iron metabolism and
ancillary role in thiolredox control. EMBO J. 30:2044–2056. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schoeneberger H, Belz K, Schenk B and
Fulda S: Impairment of antioxidant defense via glutathione
depletion sensitizes acute lymphoblastic leukemia cells for Smac
mimetic-induced cell death. Oncogene. 34:4032–4043. 2015.
View Article : Google Scholar
|
|
31
|
Buşu C, Li W, Caldito G and Aw TY:
Inhibition of glutathione synthesis in brain endothelial cells
lengthens S-phase transit time in the cell cycle: Implications for
proliferation in recovery from oxidative stress and endothelial
cell damage. Redox Biol. 1:131–139. 2013. View Article : Google Scholar
|
|
32
|
Hall MD, Marshall TS, Kwit AD, Miller
Jenkins LM, Dulcey AE, Madigan JP, Pluchino KM, Goldsborough AS,
Brimacombe KR, Griffiths GL, et al: Inhibition of glutathione
peroxidase mediates the collateral sensitivity of
multidrug-resistant cells to tiopronin. J Biol Chem.
289:21473–21489. 2014. View Article : Google Scholar : PubMed/NCBI
|
